The latest update is out from BioMarin Pharmaceutical ( (BMRN) ).
On February 20, 2025, BioMarin Pharmaceutical’s Board of Directors expanded from eleven to twelve members, appointing Timothy P. Walbert as an independent director effective February 24, 2025. Mr. Walbert will receive standard director fees and a pro rata share of the 2024 annual award of $400,000 in restricted stock units, with shares vesting before the next annual meeting of stockholders. This appointment does not result from any arrangement or related party transaction.
More about BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative therapies for serious diseases and medical conditions.
YTD Price Performance: 2.65%
Average Trading Volume: 1,541,846
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.01B
Find detailed analytics on BMRN stock on TipRanks’ Stock Analysis page.